Literature DB >> 25339035

Immunohistochemistry subtypes (ER/PR/HER) of breast cancer: where do we stand in the West of Saudi Arabia?

Mohamad Nidal Khabaz1.   

Abstract

In Saudi Arabia, cancer of breast is ranked the most frequent neoplasm and second source of cancer death in the female population. Breast cancer (BC) fast diagnosis, prognosis and medication management necessitate, these days, immunohistochemistry (IHC) assessment of hormone receptors and HER2 expression profile. The present report defines the IHC profile of ER, PR and HER2 in Saudi female breast neoplasms of ductal and lobular types and associations ER, PR and HER2 expression patterns with various clinicopathological factors (age, type of tumor, size, laterality, histological grade, and involvement of axillaries lymph nodes). Ninety nine cases of breast tumors were recruited from the pathology department archive of King Abdulaziz University Hospital, Kingdom of Saudi Arabia. ER, PR and HER2 expression was assessed using IHC staining. Ductal carcinomas with a variety of histological grades constituted 88 (88.8%) of total cases. Seventy four (77.8%), 59 (62.1%), and 35 (36.8%) of ductal carcinomas showed positive staining for ER, PR and HER2, in that order. Remaining breast cancer cases were four (4%) lobular carcinomas and two (2%) mixed form of ductal and lobular types, which were ER+, PR+, and HER2-. Breast cancer expression pattern of ER, PR and HER2 in Saudi female is different from that of Tunisian and Jordanian female populations and closer to the expression pattern of Egyptian, Lebanese, Iraqi and western country females. Furthermore, the present study found two IHC patterns of breast cancer ER+/PR-/HER2+ (5%) and ER+/PR-/HER2- (11.1%), which had not been reported in other Arabic studies. Thus the rates of IHC expression patterns in breast cancer show some variation among Arabic female populations.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25339035     DOI: 10.7314/apjcp.2014.15.19.8395

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  4 in total

1.  Efficacy of TCH/TEC neoadjuvant chemotherapy for the treatment of HER-2-overexpressing breast cancer.

Authors:  Weicai Chen; Jinsong He; Shufen Song; Min Wang; Huisheng Wu; Xianming Wang
Journal:  Oncol Lett       Date:  2015-01-28       Impact factor: 2.967

2.  First report on molecular breast cancer subtypes and their clinico-pathological characteristics in Eastern Morocco: series of 2260 cases.

Authors:  Manal Elidrissi Errahhali; Mounia Elidrissi Errahhali; Meryem Ouarzane; Tijani El Harroudi; Said Afqir; Mohammed Bellaoui
Journal:  BMC Womens Health       Date:  2017-01-09       Impact factor: 2.809

3.  Comparison of Clinico-Pathological Presentations of Triple-Negative versus Triple-Positive and HER2 Iraqi Breast Cancer Patients.

Authors:  Nada A S Alwan; Furat N Tawfeeq
Journal:  Open Access Maced J Med Sci       Date:  2019-10-14

4.  Changing Trends in Estrogen Receptors/Progesterone Receptors/Human Epidermal Growth Factor Receptor 2 Prevalence Rates Among Jordanian Patients With Breast Cancer Over the Years.

Authors:  Anas M Alsughayer; Tamara Z Dabbagh; Rashid H Abdel-Razeq; Ghada N Al-Jussani; Salam Alhassoon; Maher A Sughayer
Journal:  JCO Glob Oncol       Date:  2022-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.